Heart-lung transplantation

Kofidis, T, De Bruin, J. L., Hoyt, G., Ho, Y., Tanaka, M., Yamane, T, Lebl, D. R., Swijnenburg, R. J., Chang, C. R, Quertermous, T., and Robbins, R. C. 2005a. Myocardial restoration with embryonic stem cell bioartificial tissue transplantation. /. Heart Lung Transplant, 24,737-744. 

Cyclosporine and tacrolimus are calcineurin inhibitors that are administered as part of immunosuppressive regimens in kidney, liver, heart, lung, and bone marrow transplant recipients. In addition, they are used in autoimmune disorders such as psoriasis and multiple sclerosis. The pathophysiologic mechanism for ARF is renal vascular vasoconstriction.41 It often occurs within the first 6 to 12 months of treatment, and can be reversible with dose reduction or drug discontinuation. Risk factors include high dose, elevated trough blood concentrations, increased age, and concomitant therapy with other nephrotoxic drugs.41 Cyclosporine and tacrolimus are extensively metabolized by... 

Hyperlipidemia is seen in up to 60% of heart, lung, and renal transplant patients and greater than 30% of liver transplant patients.64 66 As a result of elevated cholesterol levels, transplant recipients are not only at an increased risk of atherosclerotic events, but emerging evidence also shows an association between hyperlipidemia and allograft vasculopathy.66 Hyperlipidemia, along with other types of cardiovascular disease, is now one of the primary causes of morbidity and mortality in long-term transplant survivors.67... 

Neuringer IP, Chalermskulrat W, Aris R. Obliterative bronchiolitis or chronic lung allograft rejection a basic science review. J Heart Lung Transplant 2005 24 3-19. 

Vagal neuropathy in diabetes mellitus [145, 146] and truncal vagotomy [147] may markedly change intestinal motility, as do heart-lung transplantation [148]. Spinal cord lesions also alter gut function, but the outlet obstruction due to failure of the striated muscles involved in defecation is more important than the enteric smooth muscle effects [149]. 

Mathias JR, Baskin GS, Reeves-Darby VG, Clench MH, Smith LL, Calhoon JH Chronic intestinal pseudoobstruction in a patient with heart-lung transplant. Dig Dis Sci 1992,37 1761-1768. 

Perrault LP, Malo O, Bidouard JP, Villeneuve N, Vilaine JP, Vanhoutte PM (2003) Inhibiting the NO pathway with intracoronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation. J Heart Lung Transplant 22 439-451... 

Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The registry of the international society for heart and lung transplantation seventeenth official report 2000. J Heart Lung Transplan. 2000 19 909-931. 

Cyclosporine has been approved for use in allogeneic kidney, liver, and heart transplant patients and is under study for use in pancreas, bone marrow, single lung, and heart-lung transplant procedures. It is recommended that corticosteroids, such as prednisone, be used concomitantly, although at half or less of their usual dose. Such combined therapy leads to fewer side effects, a decreased incidence of infectious complications, efficacy of lower doses of cyclosporine, and a better history of patient survival. 

Ahmed SM, Banner NR, Dubrey S W Low cyclosporin-A level due to Saint-John s-wort in heart transplant patients (letter). J Heart Lung Transplant 20 795, 2001... 

It is used to prevent graft rejection after kidney, liver, heart, lung, pancreas transplant or bone marrow transplantation and psoriasis not responding to conventional therapy. 

Reichenspurner H Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 2005 24 119. [PMID 15701425]... 

The first combined heart-lung transplant was performed in 1981 at Stanford University. Combined heart-lung donors need to satisfy both the requirements already described separately. Combined heart-lung transplant is recommended in patients with congenital problems affecting these organs, pulmonary hypertension and/or cystic fibrosis. The recipients for the combined transplant are recommended to be less than 55 years old. Survival rates are 79, 66, and 54% at 1 month, 1 year and 3 years, respectively, after transplantation. 

Betkowski AS, Graff R, Chen JJ, HauptmanPJ. 2002. Panel- reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant. 21 644-650. 

Mancini MC. 2006. Heart-lung transplantation, www.emedicine.com/med/topic2063.htm. 

Pinderski LJ, Kirklin JK, McGiffin D, Brown R, et al. 2005. Multi-organ transplantation Is there a protective effect against acute and chronic rejection J Heart Lung Transplant. 24 1828-1833. 

Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, Wallwork J. Prostacyclin (epo-prostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993 70(4) 366-70. 

Schofield RS, Hill JA, McGinn CJ, Aranda JM. Hormone therapy in men and risk of cardiac allograft rejection. J Heart Lung Transplant 2002 21(4) 493-5. 

Iwata, A., Sai, S., Moore, M., Nyhuis, J., de Fries-Hallstrand, R., Quetingco, G.C. et al. (2000) Gene therapy of transplant arteriopathy by hposome-mediated transfection of endothelial nitric oxide synthase. J. Heart Lung Transplant, 19, 1017-1028. 

TABLE 6.2. The Effect of Size of the FSC/SSC Gate on Determination of the Characteristics of Cells Within that Gate Peripheral Blood Mononuclear Cells from a Heart/Lung Transplant Patient ... 

Grady K, Jalowiec A, Grusk B, et al. 1992. Symptom distress in cardiac transplant candidates. Heart Lung 21 434. 

Reinlib L, Reid L. Cell transplantation as future therapy for cardiovascular disease A Workshop of the National Heart, Lung, and Blood Institute. Circulation 2000 101 e182-el 87. 

---